Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires $50,375.84 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III bought 22,192 shares of the stock in a transaction on Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,375.84. Following the acquisition, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. This trade represents a 45.62 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Perspective Therapeutics Stock Down 8.2 %

Shares of Perspective Therapeutics stock traded down $0.16 on Friday, hitting $1.80. The company had a trading volume of 1,189,656 shares, compared to its average volume of 1,013,026. The stock has a 50-day moving average of $2.77 and a 200-day moving average of $5.91. Perspective Therapeutics, Inc. has a twelve month low of $1.79 and a twelve month high of $19.05.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Finally, Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $14.44.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $33,000. Intech Investment Management LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at approximately $137,000. Aigen Investment Management LP bought a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $34,000. National Bank of Canada FI lifted its stake in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Perspective Therapeutics during the 3rd quarter worth approximately $152,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.